-
Beware of the impact of drug price linkage before mass purchase!
Time of Update: 2021-06-17
The most likely reason is that the volume purchase prices of various regions from last year to the present have been collected by the country's volume purchases, resulting in a low price limit .
-
Pfizer pneumococcal 20-valent conjugate vaccine approved by the U.S. FDA
Time of Update: 2021-06-17
The press release stated that this is the first approved vaccine against 20 pneumococcal serotypes that cause most aggressive diseases and pneumonia, including 7 serotypes that cause 40% of pneumococcal disease cases and deaths in the United States .
-
Shanghai Pharmaceuticals duloxetine hydrochloride enteric-coated tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-06-17
(hereinafter referred to as “Shanghai Pharmaceuticals Zhongxi”) has received the relevant duloxetine hydrochloride enteric-coated tablets issued by the State Food and Drug Administration.
In January 2020, Shanghai Pharmaceuticals Zhongxi submitted an application to the State Food and Drug Administration for the consistency evaluation of the generic drug and was accepted .
-
Liu Guochang, independent director of Boji Pharmaceuticals, resigns after his term of office expires
Time of Update: 2021-06-17
Liu Guochang has served as an independent director in the company for six years.
Liu Guochang will no longer hold any position in the company after the resignation report takes effect .
-
Hengrui Medicine's Carrelizumab was approved for the world's first first-line nasopharyngeal cancer indication
Time of Update: 2021-06-16
Recently, the PD-1 inhibitor Carrelizumab (Erica®) independently developed by Hengrui Medicine has officially obtained the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (NMPA), approving Carrelizumab Monoclonal antibody combined with cisplatin and gemcitabine is used for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma .
-
my country's 21 new crown vaccines enter clinical trials
Time of Update: 2021-06-16
Relevant departments pay close attention to virus mutations and other issues my country's 21 new crown vaccines have entered the clinical trial stage.
-
Hengrui Pharmaceuticals Carrelizumab Approved for First-line Treatment of Nasopharyngeal Carcinoma
Time of Update: 2021-06-16
According to Hengrui Medicine, the approval of the new indication of Carrelizumab is based on the CAPTAIN-1ST study .
At the just-concluded 2021ASCO annual meeting, Hengrui Medicine and Junshi Bio-PD-1 inhibitors both announced numerous research progress .
-
Luye Pharma’s new antidepressant drug Ansufaxine Hydrochloride Sustained-Release Tablets was accepted by CDE
Time of Update: 2021-06-16
On June 10th, Luye Pharmaceutical Group announced that its self-developed Chinese chemical drug Class 1 new drug Ansufacine Hydrochloride Sustained-Release Tablets (LY03005) has been officially accepted by the Drug Evaluation Center of the China National Medical Products Administration .
-
Teva again initiates patent lawsuit against Eli Lilly over migraine drug Emgality
Time of Update: 2021-06-16
Up to now, there have been three monoclonal antibody migraine preventive drugs that target CGRP or its receptors: Novartis and Amgen Aimovig, Eli Lilly Emgality and Teva Ajovy .
-
AstraZeneca's new crown vaccine is linked to slightly increased risk of bleeding disorders
Time of Update: 2021-06-16
At 23:00 on June 9th, Beijing time, the top international academic journal "Nature Medicine" (Nature Medicine) published online a study completed by the British team, entitled "First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic" , thromboembolic and hemorrhagic events in Scotland" .
-
More WHO research finds to rewrite the timeline of the new crown epidemic
Time of Update: 2021-06-16
In December last year, another group of researchers from the University of Milan reported in the US "Journal of New Infectious Diseases" that a 4-year-old boy's oropharyngeal swab sample collected on December 5, 2019 tested positive for the new crown virus .
-
Shi Yi: To do scientific research is to face the major strategic needs of the country
Time of Update: 2021-06-16
" Shi Yi said: "The so-called research period means that when emergencies occur, we must gather forces in a short time and quickly produce scientific research results .
-
"Nature": The spread of new coronavirus variants in Europe is related to travel
Time of Update: 2021-06-16
The study pointed out that this new variant 20E (EU1) new coronavirus, which is believed to have appeared in Spain, has been introduced to European countries hundreds of times by summer travelers .
-
The application status of new solid dosage forms for oral administration in children
Time of Update: 2021-06-16
Children's oral solid preparations in China are relatively simple, mostly ordinary tablets, followed by dispersible tablets and sustained-release tablets, and the rest of the tablets account for only 10%.
-
Yangtze River will win $3 billion in oral hypoglycemic drugs!
Time of Update: 2021-06-16
According to data from Meinenet, in 2020, the total sales of sitagliptin tablets in the terminals of public medical institutions in China and physical pharmacies in Chinese cities will exceed 1.
-
New coronavirus vaccination status: 80,896,200 doses!
Time of Update: 2021-06-16
New coronavirus vaccination status: 80,896,200 doses!
New coronavirus vaccination status: 80,896,200 doses!
New coronavirus vaccination status: 80,896,200 doses!
As of June 8, 2021, 31 provinces (autonomous regions and municipalities directly under the Central Government) and Xinjiang Production and Construction Corps have reported a total of 80,8962,000 doses of new coronavirus vaccine .
-
The 2021 medical insurance catalog adjustment starts!
Time of Update: 2021-06-16
The medicines in the medical insurance catalogue are the exclusive negotiated medicines whose agreement expires on December 31, 2021, and the payment standard needs to be re-determined in accordance with the agreement; from January 1, 2016 to June 30, 2021, approved by the National Food and Drug Administration , Indications or functional indications have undergone major changes, and the company takes the initiative to declare and adjust drugs that limit the scope of payment .
-
China Disease Control: The best way to prevent new coronary pneumonia is to get vaccinated
Time of Update: 2021-06-16
Medium disease control: the best way to prevent new coronary pneumonia is still vaccination At a press conference held by the Joint Prevention and Control Mechanism of the State Council today (11th) , Wang Huaqing, chief expert of the China Centers for Disease Control and Prevention's immunization program, said in response to questions about the effectiveness of vaccine protection that the best way to prevent new coronary pneumonia is to get vaccinated .
-
Qilu enters the market with annual sales of $1.9 billion blockbuster drugs and Chengdu Beite competes for the first imitation
Time of Update: 2021-06-16
Chengdu Better Pharmaceuticals submitted an application for the imitation of emtricitabine propofol tenofovir tablets (acceptance number CYHS1900772) in November 2019, and the acceptance number is currently under review and approval .
-
Notice of the Fifth Batch of National Clinical Medical Research Center Application Work
Time of Update: 2021-06-16
57 All relevant units: In accordance with the overall deployment of the "National Clinical Medical Research Center Five-Year (2017-2021) Development Plan" (Guoke Fashe [2017] No.
5. The construction review of the National Clinical Medical Research Center includes three procedures: formal review, material review, and comprehensive review .
